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Background: Initiatives to improve early detection and access to HIV services have increased over
time. We assessed the immune status of patients at initial presentation for HIV care from 1997-2007
in 13 US and Canadian clinical cohorts.
Methods: We analyzed data from 44,491 HIV-infected patients enrolled in the North American –
AIDS Cohort Collaboration on Research and Design. We identified first presentation for HIV care
as the time of first CD4+ T-lymphocyte (CD4) measurement and excluded patients who prior to this
date had HIV RNA measurements, evidence of antiretroviral exposure, or a history of AIDS-defining
illness. Trends in mean CD4 count (measured as cells/mm3) and 95% confidence intervals ([,]) were
determined using linear regression adjusted for age, gender, race/ethnicity, HIV transmission risk
and cohort.
Results: Median age at first presentation for HIV care increased over time (range 40-43 years,
p<0.01), while the proportion of patients with injection drug use HIV transmission risk decreased
(26% to 14%, p<0.01) and heterosexual transmission risk increased (16% to 23%, p<0.01). Median
CD4 at presentation increased from 256 (IQR: 96-455) to 317 (IQR: 135-517) in 1997 to 2007
(p<0.01). The proportion with a CD4 count ≥350 at first presentation also increased from 1997 to
2007 (38% to 46%, p=<0.01). The estimated adjusted mean CD4 count increased at a rate of 6 [5,
7] per year.
Conclusion: CD4 count at first presentation for HIV care has increased annually over the past 11
years, but has remained <350 cells/mm3, suggesting the urgent need for earlier HIV diagnosis and
treatment.
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BACKGROUND
Approximately 25% of the estimated 1.1 million Americans and 58,000 Canadians living with
HIV infection are unaware they are infected [1,2]. Among the estimated 56,000 new infections
occurring each year in the US [3], over half are estimated to be transmitted by persons who are
unaware of their HIV infection [4]. In the US from 2000 to 2006, rates for a history of ever
being tested for HIV infection have remained stable at less than 40%; among persons with
established risk factors for HIV during 2006 only 23% were tested [5]. In Canada in 2003, a
general population survey found that 29% of women and 24% of men reported ever being
tested for HIV [6]; in 1996, 71% of men who have sex with men (MSM), 62% of injection
drug users (IDUs) and 51% of high-risk heterosexuals reported ever being tested, although
these higher proportions may be due to testing for research participation [2]. Even among
pregnant women in the US in 2006, only 61% had been tested despite long-standing
recommendations and extensive efforts to incorporate routine opt-out testing into pregnancy
care [5]. Similar guidelines for testing during pregnancy exist in Canada; however, prenatal
HIV screening programs vary. Data from 2002 to 2006 show the proportion of pregnant women
screened for HIV ranges from 60% in Manitoba to ≥95% in Alberta, Newfoundland and
Labrador, and the Northwest Territories [2]. Persons who are unaware of their HIV status are
unable to benefit from the advances made in HIV treatment, and late presentation for HIV care
is associated with higher mortality even after receipt of antiretroviral therapy [7,8], and a
diminished recovery of CD4+ T-lymphocytes (CD4) [9]. Late presenters also have a prolonged
opportunity to transmit HIV while unaware of their HIV infection.
To assess when individuals are entering HIV care, we analyzed the immune status in patients
who newly presented for care over the past 11 years in the US and Canada. Given the
improvements that have occurred in HIV therapy, and efforts to improve early diagnosis and
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treatment of HIV [10-12], our objective was to assess whether patients presented for HIV care
earlier in the course of their HIV infection over time and to determine factors associated with
a later presentation to HIV care.
METHODS
Study design and population
All patients were part of the North American Cohort Collaboration on Research and Design
(NA-ACCORD), a regional group of the International Epidemiological Databases to Evaluate
AIDS (IeDEA) project. The NA-ACCORD is a multisite collaboration of 8 interval and 14
clinical cohort studies with sites in the US and Canada [13]. Each cohort's participation in NA-
ACCORD was approved by the respective local institutional review boards. Contributing
cohorts have used standardized methods of data collection and have submitted demographic,
treatment, clinical, laboratory, and vital status data on enrolled participants.
Inclusion criteria and variables of interest
Only participants from clinical cohorts were included in this study because our interest was in
the degree of immunosuppression at first presentation for HIV clinical care; the interval
research cohorts in the NA-ACCORD do not administer clinical care. All of the 14 clinical
cohorts agreed to participate in this study although one was excluded because their study
population enrollment criteria restricted to those in later stages of HIV disease. These 13
clinical cohorts have clinical sites in the following US states and territories and Canadian
provinces: Alberta, Alabama, California, Colorado, Florida, Georgia, Illinois, Maryland,
Michigan, Missouri, New York, North Carolina, Ohio, Ontario, Oregon, Pennsylvania,
Quebec, Tennessee, Texas, Washington and Washington DC. Due to the geographic dispersion
of these clinical cohorts where individuals are receiving their HIV care, the possibility that an
individual is participating in more than one of the clinical cohorts is low.
We analyzed data from HIV-infected adults (≥18 years of age) who first presented for clinical
care between January 1997 through December 2007, where first presentation for HIV clinical
care was defined as the date (month and year) at which the first CD4 count was reported. The
clinical cohorts of the NA-ACCORD are well-established, and have procedures to determine
medical histories at first presentation for care. HIV-related treatments, laboratory results and
diagnoses prior to enrollment are routinely recorded.
Several methods were used to eliminate patients who might have been receiving HIV care prior
to their first recorded CD4 count. First, we excluded patients who were taking antiretroviral
therapy or had an HIV RNA measurement recorded prior to the date of the first CD4
measurement. Second, we also excluded those patients who had an AIDS-defining diagnosis
recorded more than 3 months prior to the first CD4 measurement. A period of 3 months prior
to the first CD4 measurement was utilized to include those who may have had an AIDS-defining
diagnosis at the time of HIV diagnosis and to exclude those who may have been seeking care
elsewhere. Third, for each cohort, we excluded all individuals contributing data during the first
year that the cohort contributed data to the NA-ACCORD who may have been patients
previously in care but contributing data to a new cohort data capture system. Although these
criteria might not completely exclude earlier presentation for HIV care (particularly
presentation at clinical sites outside of the participating cohort) we believe that these criteria
minimize the possibility that the patients in this study had presented for HIV care at an earlier
time.
The first measured CD4 was our outcome of interest. The month and year in which the CD4
was measured were recorded. If there was more than one CD4 measurement in the first month
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at presentation for HIV care, we calculated the mean CD4 count for the month. Other
information obtained at first presentation for care included self-reported date of birth, gender,
race/ethnicity and HIV transmission risk group. Race/ethnicity was categorized as black, white,
Latino and other/unknown. HIV transmission risk group was categorized as MSM, IDU,
heterosexual, and other/unknown. Participants with both sexual and IDU transmission risk
were categorized as IDU.
Statistical Analysis
Statistical comparisons of demographic and clinical characteristics across calendar dates were
made using the Cochran-Armitage trend test for categorical variables (e.g. country of care,
gender, race/ethnicity and HIV transmission risk group) or using the Cuzick trend test for
continuous variables (e.g. age, CD4 count). We determined the median absolute CD4 count at
first presentation for HIV clinical care annually from 1997 through 2007. Multivariate linear
regression models were used to describe the annual trends in estimated mean CD4 count using
a linear variable for year and adjusting for cohort demographic and risk characteristics; 95%
confidence intervals ([,]) were also estimated using these models. Two-way interactions
between calendar year and age, gender, race/ethnicity and HIV transmission group were
considered. Nonlinearity of the relationship between calendar time and CD4 count at first
presentation for HIV care was assessed by including a quadratic term for calendar year. Results
with a two-sided p-value of <0.05 were considered statistically significant. Analyses were
conducted using SAS, version 9.
RESULTS
A total of 67,961 patients receiving clinical care at one of the participating NA-ACCORD sites
between 1997 and 2007 had complete date and CD4 measurement information. Of these,
21,983 (32%) had a prior history of antiretroviral therapy or HIV RNA results and 1,487 (2%)
had an AIDS-defining diagnosis recorded more than 3 months prior to the first recorded CD4
count. Thus, our study population consisted of 44,491 HIV-infected individuals.
The characteristics of individuals who first presented for HIV care each year are shown in
Table 1. Over time, the median age at first presentation increased (range: 40 – 43 years, p<0.01).
The proportion of white patients decreased over time (from 30% in 1996 to 24% in 2007,
p<0.01) while the proportion of black patients fluctuated, but remained higher than the
proportion of white and Latino patients (p<0.01). The proportion of patients with IDU
transmission risk decreased (26% in 1997 to 14% in 2007, p<0.01) and heterosexual
transmission risk increased (16% in 1997 to 23% in 2007, p<0.01). There was a slight increase
in the proportion of Canadian patients, however the proportion remained <10% over time
(p<0.01).
The median CD4 count of the study population increased over time but the changes were within
a range of 61 cells/mm3 over all 11 years (Figure 1). The percentage of patients presenting
with a CD4 count ≥350 cells/mm3 increased from 38% in 1997 to 46% in 2007 (p<0.01) (Figure
1). The overall estimated annual change in mean CD4 count was 6 [5,7] cells/mm3, adjusting
for age, gender, race/ethnicity, transmission risk group and cohort. The quadratic term for
calendar year was not significant (p=0.27), suggesting the relationship between calendar year
and CD4 count at first presentation for HIV care was not U-shaped. However, there were
significant interactions between the change in CD4 count per year with race/ethnicity (p=0.01)
and with transmission risk group (p<0.01), but not gender (p=0.13).
Table 2 displays the results from the overall and stratified multivariate models. Although
females had higher observed mean CD4 counts in 1997, the estimated mean increase in CD4
count per year among females was less than males (females: 5 [3,7] cells/mm3 per year; males:
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6 [5,7] cells/mm3 per year). Latinos had the greatest annual increase in estimated mean CD4
count since 1997 (9 [7,12] cells/mm3) and blacks had the smallest increase (5 [3,7] cells/
mm3). Latinos showed a lower observed (293 cells/mm3) mean CD4 count in 1997 compared
with whites (328 cells/mm3) and blacks (305 cells/mm3). The estimated annual change in mean
CD4 count at first presentation was 7 [6,9] cells/mm3 among MSM, 5 [3,7] cells/mm3 among
IDU and 2 [0, 4] cells/mm3 among those with heterosexual transmission risk. MSM showed
low observed mean CD4 counts in 1997 (303 cells/mm3) and those with IDU and heterosexual
transmission risk had a slightly higher observed mean CD4 count in 1997 (334 and 328 cells/
mm3, respectively).
Patients who were older had lower CD4 counts at first presentation for HIV care, with an
average decrease of 24 [−27, −21] cells/mm3 at the time of first presentation for care over 11
years, adjusting for gender, race/ethnicity, transmission risk group and cohort. The interaction
of age and calendar time on CD4 count at first presentation for HIV care was borderline
statistically significant (p=0.05).
After stratifying by cohort, n=6 cohorts showed a significant increase in estimated mean annual
change in CD4 count at presentation (range: 5 to 8 cells/mm3) and n=7 cohorts showed no
difference in estimated mean CD4 count over time (Figure 2). Cohort 3 had a borderline
significant decrease of 5 cells/mm3 per year. Participants in cohort 3 had the highest mean CD4
count in 1997, 78% were black and 53% reported heterosexual transmission risk – all factors
potentially contributing to this decrease.
DISCUSSION
Since the mid-1990's, public health efforts have focused on identifying HIV infection at an
early stage, which should imply an increase in patients presenting for HIV care earlier in the
course of disease. Our data from multiple clinical sites across the US and Canada indicate that
although CD4 count at presentation has increased since 1997, most patients continue to first
present for HIV care with a CD4 count below 350 cells/mm3, the level at which initiation of
antiretroviral therapy is currently recommended by multiple major national guideline
committees for persons living in developed countries [14-18]. Stratifying out results by cohort
demonstrated our findings were not an artifact of the combined data set. Knowing that within-
patient variation in CD4 measurements is approximately 25% with increased variation at lower
CD4 counts, our estimated mean annual increase in the CD4 count is likely of little clinical
relevance [19].
Several smaller regional studies have also found that patients present late in the course of HIV
infection. Among 1,209 patients who newly presented for care in an infectious diseases clinic
in Alabama, 41% had already progressed to AIDS [20]. In South Carolina from 2001-05, 41%
of AIDS cases were diagnosed within 1 year of HIV diagnosis [21], in North Carolina from
2000-03, 50% had a CD4 count <200 cells/mm3 at first presentation for HIV care [22], in
Washington DC from 1997-2006, 66% of AIDS cases were diagnosed within one year of HIV
diagnosis [23], and in Maryland the CD4 count at first presentation for HIV care declined from
371 to 276 cells/mm3 from 1990 to 2006 [24]. A Centers for Disease Control and Prevention
(CDC) analysis of data collected in 33 US states from 2001-03 found a median CD4 count
within 12 months of diagnosis of HIV-infection of only ~170 cells/mm3 [25]. In a population
of primarily Canadian Aboriginals newly-diagnosed patients with HIV from 1998-2003, the
median CD4 count was 330 cells/mm3; 28% had a CD4 count <200 cells/mm3 at diagnosis
and median time to care was 27 days [26]. Another study from Calgary, Canada found that
39% of patients first presented with a CD4 count <200 cells/mm3 and had care costs that were
200% higher than for patients who presented with higher CD4 counts [27]. In addition to age,
gender, and race/ethnicity [20,22,24,26], these studies have also shown associations between
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CD4 count at first presentation and insurance type [20] and nonmetropolitan residence [26] in
multivariate analyses; we were unable to systematically measure these variables in our
participating cohorts.
Over time, the demography of the HIV epidemic in the US and Canada has shifted [2,28].
Although the greatest proportion of persons diagnosed with HIV/AIDS remain MSM, the
proportions of persons diagnosed with HIV/AIDS who are women, who are of minority race/
ethnicity, and who have as their principal HIV transmission risk factor IDU or heterosexual
contact, have increased. US national surveillance data from 2000-2003 demonstrated that late
testers (persons who had their first positive HIV test within one year before diagnosis of AIDS)
were significantly more likely to be younger (aged 18-29 years), black or Latino, and to have
been infected through heterosexual contact [29]. In Canada from 1997-2004, various studies
report younger individuals (age 25-34 years), and those who are higher-risk for acquiring HIV
infection (i.e. MSM, IDUs, ≥2 partners in the last year among heterosexuals) were more likely
to be tested [2]. We did not see this shift to younger patients at time of presentation, nor
significantly greater percentages among Latino HIV-infected patients. However, black
participants had the smallest mean annual increase in CD4 count at first presentation of any
racial group. Similarly, the estimated mean annual increase in CD4 count among those with
heterosexual transmission risk was dramatically lower than other risk groups. National
surveillance data coupled with our findings suggest the number of blacks and high-risk
heterosexuals entering into care at a later stage of disease will grow; however, the impact might
be diminished with the expansion of routine HIV testing that would likely result in earlier
diagnosis and entry into care.
The public health implications for our findings are clear: 1) delayed diagnosis reduces survival;
and 2) individuals entry into HIV care had lower CD4 counts than the guideline for
antiretroviral therapy initiation. A study from the Netherlands found that mortality after starting
antiretroviral therapy could be reduced by 20% if patients were to present for HIV care with a
CD4 count ≥400 cells/mm3 [8]. Current guidelines recommend starting antiretroviral therapy
before the CD4 count reaches 350 cells/mm3, and recent data from across the US and Canada
suggests that initiating therapy at even higher CD4 levels improves survival [30]. This
underscores the importance of identifying infection and engaging in HIV care at a earlier stage
than is occurring currently.
A delay in presentation for treatment not only increases the chance of clinical disease
progression for that patient but also increases the risk of ongoing transmission. Early effective
antiretroviral treatment can lower circulating HIV-1 RNA levels, thereby decreasing the risk
of HIV transmission [31-33]. Patients who learn they are infected with HIV may reduce their
HIV-1 RNA with the effective antiretroviral treatment and reduce their risk-taking behavior,
consequently resulting in reduced risk of transmitting HIV to others [34].
Our results found no significant differences in CD4 trends over time based by gender. Some
women were likely tested as part of pre-natal screening (pregnant women are not excluded
from these clinical care cohorts), and it is possible the CD4 count at which they presented for
care was higher than the CD4 count at which non-pregnant women were tested and
subsequently entered care. As the circumstances under which women were tested and
subsequently entered care were unknown, we were unable to determine differences in CD4
counts at first presentation for care for these two groups of women.
There is clearly a need for earlier HIV diagnosis and intervention. Relying on clinical indicators
for HIV infection to prompt testing is inadequate. A study from a large managed care
organization in California indicated that only 22% of patients in medical care had at least one
of eight clinical indicators suggested in the literature as reasons to test for HIV within one year
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of being diagnosed [35]. A recent study among US veterans suggested that delayed presentation
for HIV care is not a result of lack of medical care access for this population [36].
HIV testing is entering a new era as practice guidelines have recently changed to address the
need for increased, earlier testing and with linkage to care. In September 2006, the CDC
released Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant
Women in Health-Care Settings [37]. These advised routine HIV screening in health-care
settings of adults and adolescents aged 13-64 years and of all pregnant women with prior
notification and opt-out allowed. Separate informed consent, a barrier to HIV testing [38,39],
is no longer recommended. More recently, the American College of Medicine released
recommendations for universal HIV screening [40]. If we are to make any impact on improving
the health of HIV-infected persons and reducing the spread of the virus, public health officials,
hospital administrators, and clinicians will need to adopt these recommendations into practice
and change policies (e.g., legal requirements for informed consent for HIV testing and
elimination of the need for HIV pretest counseling in most US states and Canadian provinces)
to ensure that more persons are screened and referred for early treatment.
In summary, between 1997 and 2007 in the US and Canada, there was little improvement in
the immunologic stage of HIV infection among patients entering HIV care. Patients presented
with relatively low CD4 counts, at a stage of disease where the effectiveness of treatment is
reduced and providing an extended opportunity to transmit HIV to others. These data provide
strong evidence that implementation of new strategies for earlier HIV testing and effective
linkage into care are urgently needed.
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Median CD4 count (and interquartile range), and the percentage of patients with a CD4 count
≥350 cells/mm3, at first presentation for HIV clinical care, NA-ACCORD 1997-2007
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Observed mean CD4 count (year) and estimateda mean annual change in CD4 count and 95%
confidence interval at first presentation for HIV clinical care, by cohort, NA-ACCORD, 1997
-2007
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Table 2
Observed mean CD4 count in 1997 and 2007 and estimated mean annual change in CD4 count at first presentation
for HIV clinical care, NA-ACCORD 1997-2007
Observed mean CD4 count (standard deviation) Estimated change in CD4
count (95%CI) per year
(1997-2007)a
1997 2007
Overallb 307 (259) 360 (283) 6 (5, 7)
Models stratified by
sexc
Male 300 (255) 353 (278) 6 (5, 7)
Female 349 (281) 395 (303) 5 (3, 7)
Models stratified by
race/ethnicityd
White 328 (271) 382 (280) 6 (5, 8)
Black 305 (261) 328 (279) 5 (3, 7)
Latino 293 (246) 383 (301) 9 (7, 12)




MSM 303 (255) 374 (263) 7 (6, 9)
IDU 334 (260) 358 (311) 5 (3, 7)
Heterosexual 328 (279) 337 (284) 2 (0, 4)
Other/Unknown 280 (249) 363 (289) 8 (7, 10)
Abbreviations: NA-ACCORD= North American Cohort Collaboration on Research and Design, CI=confidence interval, MSM=men who have sex
with men, IDU=injection drug user
a
Estimated mean CD4 count, estimated change in CD4 count per year from 1996-2007 and 95% confidence intervals from multivariate linear regression
models.
b
Adjusted for age, gender, race/ethnicity, HIV transmission risk group and cohort.
c
Adjusted for age, race/ethnicity, HIV transmission risk group and cohort.
d
Adjusted for age, gender, HIV transmission risk group and cohort.
e
Adjusted for age, gender, race/ethnicity and cohort.
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